NeoVolta

NEOV · NASDAQ

$2.07−$0.085 (−3.94%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.16

NEOV analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $9.94 (+380.4% upside)

Low: $5.05
Now: $2.07
High: $15.75

Upgrades and downgrades

The latest rating actions, newest first

NEOV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Needham	Sep 24, 2026	Maintains	Buy	$8.00	30%
Needham	Sep 15, 2026	Maintains	Buy	$8.00	30%
Northland Capital Markets	Jul 29, 2026	Initiates	Outperform	$15.00	60%
Needham	Jul 2, 2026	Maintains	Buy	$8.00	30%
Lake Street	Jun 26, 2026	Initiates	Buy	$11.00	50%
Needham	Jun 17, 2026	Initiates	Buy	$8.00	30%

The case for and against

Updated Oct 17, 2026

Bull case

NeoVolta is supported by a compelling transition from legacy operations to a scalable domestic BESS platform at Pendergrass, where Line 1 is completing commissioning and management expects first orders before year-end, with a 2QFY27 ramp and a potential Line 2 decision this year. The SK On framework is especially important because it secures 9 GWh of U.S.-made LFP cells over 2027–2031, with another 9 GWh under framework, improving supply certainty, domestic-content credentials, and the path toward mid-to-2H CY2027 production and possibly 8 GWh by CY2028. Fundamentally, the thesis is strengthened by improving bankability and funding—$20MM of secured debt, ~$30MM of cash, and a pipeline of binding PO conversion, ABL financing, customer prepayments, and Section 45X monetization—while gross margin could reach ~20-25% at full Line 1 utilization.

Bear case

NeoVolta is facing a fragile execution story where equipment installation, FEOC certification, or JV financing could slip, leaving pipeline interest unconverted and the ramp stalled. With Pendergrass still pre-revenue and delays in the August acceptance, commissioning, yield, or throughput likely pushing out the FY27-FY28 inflection, the business remains highly exposed to timing risk and potential dilution from a micro-cap ~56.6MM share base. Dependence on Chinese cells, evolving Treasury FEOC, 45X, and 48E guidance, plus customer and supplier concentration and pressure from better-capitalized rivals like Sungrow and Hithium, further weakens confidence in durable fundamental upside.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.